The FDA has accepted a resubmitted Biologics License Application for bevacizumab-vikg (ONS-5010), a potential first FDA-approved ophthalmic formulation for wet AMD, with a Class 1 review designation.

Key Highlights

  • The FDA accepted a resubmitted Biologics License Application for bevacizumab-vikg (ONS-5010) under a Class 1 review designation.
  • The application, tracked under filing identifiers, could lead to the first FDA-approved ophthalmic formulation of bevacizumab.
  • ONS-5010 targets VEGF, a key factor in wet AMD progression, and aims to provide a standardized alternative to off-label use.
  • The resubmission follows prior regulatory feedback and aligns with commercial preparations for potential U.S. market entry.
  • The product has already received marketing authorization in select European markets under the name LYTENAVA™.

The U.S. Food and Drug Administration has accepted a resubmitted Biologics License Application (BLA) for bevacizumab-vikg, an investigational ophthalmic treatment for neovascular age-related macular degeneration (wet AMD). The filing, identified by the identifiers **0001104659** and **074346**, received a Class 1 review designation, indicating an expedited evaluation process.

Developed under the product code **ONS-5010**, bevacizumab-vikg is designed to inhibit vascular endothelial growth factor (VEGF), a protein linked to abnormal blood vessel growth in wet AMD. By blocking VEGF isoforms, the therapy aims to reduce retinal vascular leakage and progression of the disease.

The resubmission follows earlier regulatory discussions and represents a step toward potential U.S. approval. In Europe, the product has already secured marketing authorization as LYTENAVA™ (bevacizumab gamma) for wet AMD, with commercial launches underway in markets such as Germany, Austria, and the UK. If approved in the U.S., it could provide a standardized, FDA-reviewed alternative to off-label bevacizumab use in ophthalmology, which currently lacks uniform manufacturing oversight.

The company behind the application has begun preparations for potential commercialization, including manufacturing and partnership activities. While the review process is underway, the outcome could influence the competitive landscape for wet AMD treatments, particularly among VEGF inhibitors.

Regulatory clarity on the application’s status may attract attention from investors focused on late-stage biotech assets. However, potential challenges, such as labeling requirements or post-approval monitoring, could affect the timeline for market availability.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.